Maobai Liu

1.2k total citations · 1 hit paper
87 papers, 815 citations indexed

About

Maobai Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Maobai Liu has authored 87 papers receiving a total of 815 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 15 papers in Pharmacology. Recurrent topics in Maobai Liu's work include Cancer Immunotherapy and Biomarkers (12 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Maobai Liu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Maobai Liu collaborates with scholars based in China and United States. Maobai Liu's co-authors include Hongfu Cai, Bin Zheng, Hongqiang Qiu, Zhichang Zhao, Longfeng Zhang, Xuemei Wu, Maohua Chen, Bin Li, Juan Wu and Xiaohong Xu and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Maobai Liu

81 papers receiving 802 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

2024 51 citations Jianxing Zhou, Maobai Liu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maobai Liu China	17	225	162	125	120	116	87	815
Estelle Marrer Switzerland	11	83 0.4×	90 0.6×	236 1.9×	64 0.5×	71 0.6×	13	885
Anton Gillessen Germany	14	96 0.4×	221 1.4×	148 1.2×	19 0.2×	260 2.2×	50	905
Benjamin Weber United States	14	220 1.0×	290 1.8×	188 1.5×	34 0.3×	45 0.4×	34	870
M B Affrime United States	14	116 0.5×	52 0.3×	95 0.8×	37 0.3×	151 1.3×	46	765
Lihong Liu China	22	151 0.7×	109 0.7×	389 3.1×	48 0.4×	102 0.9×	93	1.2k
Robin Michelet Germany	13	128 0.6×	94 0.6×	164 1.3×	42 0.3×	28 0.2×	65	703
Michel Guillaume Belgium	14	65 0.3×	44 0.3×	80 0.6×	26 0.2×	147 1.3×	28	657
Koichiro Atsuda Japan	14	90 0.4×	37 0.2×	109 0.9×	36 0.3×	86 0.7×	64	532
Xianzhang Huang China	19	125 0.6×	117 0.7×	366 2.9×	54 0.5×	79 0.7×	95	1.1k
Shenghao Tu China	20	184 0.8×	168 1.0×	514 4.1×	23 0.2×	82 0.7×	70	1.7k

Countries citing papers authored by Maobai Liu

Since Specialization

Citations

This map shows the geographic impact of Maobai Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maobai Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maobai Liu more than expected).

Fields of papers citing papers by Maobai Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maobai Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maobai Liu. The network helps show where Maobai Liu may publish in the future.

Co-authorship network of co-authors of Maobai Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Maobai Liu. A scholar is included among the top collaborators of Maobai Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maobai Liu. Maobai Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Lili, et al.. (2025). Inhaled alone versus inhaled plus intravenous polymyxin B for the treatment of pneumonia due to carbapenem-resistant gram-negative bacteria: A prospective randomized controlled trial. International Journal of Antimicrobial Agents. 65(5). 107483–107483.

Zhang, Hui, et al.. (2025). Association of NR1I2 Polymorphism with Midazolam Clearance in Mechanically Ventilated ICU Patients: A Population Pharmacokinetic and Pharmacogenetic Study. Drug Design Development and Therapy. Volume 19. 1527–1541. 1 indexed citations

Chen, Tingting, et al.. (2025). Antibiotics in the treatment of scrub typhus: A network meta-analysis and cost-effectiveness analysis. The Journal of Infection in Developing Countries. 19(1). 67–75. 1 indexed citations

Fu, Wu, et al.. (2025). Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer. Scientific Reports. 15(1). 2497–2497. 2 indexed citations

Zhuang, Shaowei, et al.. (2025). Adverse cardiac events associated with antibody-drug conjugates in cancer patients: retrospective analysis of FAERS database and RCTs. Cardiovascular Research. 121(15). 2318–2333. 1 indexed citations

Zhou, Jianxing, et al.. (2024). Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer’s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System. Annals of Pharmacotherapy. 59(3). 213–222. 1 indexed citations

Zhuang, Shaowei, et al.. (2024). Evidence-based interventions to improve sleep quality after thoracic surgery:A retrospective analysis of clinical studies. Sleep Medicine. 121. 85–93. 4 indexed citations

Zhang, Yujia, et al.. (2024). Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review. European Journal of Clinical Pharmacology. 80(7). 965–982. 1 indexed citations

Zhou, Jianxing, et al.. (2024). The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System. British Journal of Clinical Pharmacology. 91(4). 1272–1280. 3 indexed citations

10.

Chen, Tingting, et al.. (2024). Oral aripiprazole in the treatment of tic disorders in China: a cost-effectiveness analysis based on a mapping algorithm derived from a Chinese children and adolescents population. Child and Adolescent Psychiatry and Mental Health. 18(1). 97–97.

11.

Zheng, Bin, et al.. (2024). Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China. Frontiers in Oncology. 14. 1484650–1484650. 3 indexed citations

12.

Chen, Rong, et al.. (2024). Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment. Cancer Medicine. 13(3). e6708–e6708. 3 indexed citations

13.

Liu, Maobai, et al.. (2024). A two-stage ensemble learning based prediction and grading model for PD-1/PD-L1 inhibitor-related cardiac adverse events: A multicenter retrospective study. Computer Methods and Programs in Biomedicine. 255. 108360–108360.

14.

Li, Xueyong, Yi‐Ying Chen, Yi‐Ying Chen, et al.. (2024). Comparison of whole-blood sirolimus concentrations measured by EMIT-based Siemens Viva-ProE® System and LC-MS/MS in Chinese transplant patients. Journal of Pharmaceutical and Biomedical Analysis. 247. 116271–116271. 1 indexed citations

15.

Chen, Yi‐Ying, Bo Chen, Maobai Liu, et al.. (2023). Determination of polymyxin B in human plasma and epithelial lining fluid using LC-MS/MS and its clinical application in therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis. 227. 115291–115291. 16 indexed citations

16.

Chen, Shengyang, et al.. (2023). Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients. The Journal of Clinical Pharmacology. 63(9). 1036–1044. 5 indexed citations

17.

Zhou, Jianxing, et al.. (2023). Movement disorders associated with antiseizure medications: A real‐world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System. British Journal of Clinical Pharmacology. 89(11). 3389–3400. 8 indexed citations

18.

Yang, Ting, Jianxing Zhou, Jingting Wang, et al.. (2023). Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study. CPT Pharmacometrics & Systems Pharmacology. 12(9). 1238–1249. 1 indexed citations

19.

Liu, Maobai, et al.. (2021). Can Published Population Pharmacokinetic Models of Busulfan Be Used for Individualized Dosing in Chinese Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation? An External Evaluation. The Journal of Clinical Pharmacology. 62(5). 609–619. 1 indexed citations

20.

Liu, Maobai, et al.. (2019). <p>Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer</p>. Cancer Management and Research. Volume 11. 9195–9202. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact